Skip to main content
Premium Trial:

Request an Annual Quote

VizX Aims at Becoming Cash-Flow Positive by End of Year

NEW YORK, July 24 - Informatics company VizX labs intends to be cash-flow positive at the end of the year, according to an e-mail message from CEO and co-founder Thomas Ranken.


"We will develop the capacity to expand our company from new funding sources: earnings, investment, and debt," said Ranken.


VizX makes the gene expression-analysis software, a new version of which was launched earlier this month. Besides becoming cash-flow positive, Ranken said the company's "top priority" is to "build sales" for the software, which he said is responsible for the lion's share of the company's revenue.


Reached by telephone in VizX's Seattle, Wash., headquarters, Ranken said the firm intends to increase its sales staff and enter into new distribution deals.


VizX has been funded by angel investors up until now, Ranken said. He added the company is wrapping up a convertible-note round, and is talking to venture capitalists. "But ... the market is very tough."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.